EBS Emergent Biosolutions, Inc. PHARMACEUTICAL PREPARATIONS Best Pharmaceutical Stocks 2026 →

Emergent Biosolutions (EBS) Stock: Buy, Sell, or Hold?

$5.79
-0.10 (-1.70%) ▼
5d: -4.46% 30d: -19.36% 90d: +28.67%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (65%)
Quality Score
47/100
Position
OVERSOLD
30-Day Fair Range
$6.01 – $6.88
Position: OVERSOLD
Forward P/E & Valuation
5.5x CHEAP
vs 11.5x historical avg
Wall Street Target
$10.00
+72.7% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$5.51 / $7.22
Trend: Downtrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: EBS shows conflicting indicators. Wait for confirmation before entering.

Get Alerted When EBS Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$23.43
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$14.55
60.2% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.5x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: EBS is currently trading at $5.79, which is considered oversold relative to its 30-day fair value range of $6.01 to $6.88. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.5) compared to its historical average (11.5). Remarkably, the market is currently pricing in an annual earnings decline of 21.6% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, EBS is in a downtrend. Immediate support is located at $5.51, while resistance sits at $7.22.

Market Sentiment: EBS scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $10.00 (+72.7%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position OVERSOLD
Historical Trading Range $6.01 - $6.88
Company Quality Score 47/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 65.4%

Trading Range & Key Levels

30-Day Trading Range $6.01 - $6.88
Current vs Trading Range OVERSOLD
Expected Move (7 Days) ±$0.63 (11.0%)
Support Level $5.51
Resistance Level $7.22
Current Trend Downtrend
Technical data as of Nov 13, 2026

Protect Your Profits

Holding EBS? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

Institutional Signals, 13F Whale Activity & Setup Structure

Quantitative Research Feed
Active Quantitative Risk Vetoes (1)
Trap Candle Warning: bull engulfing at 20-bar low, RSI div (42 > 42)
Phase & Gamma Walls CONSOLIDATION
Days in Phase: 29d (62% conf)
Technical Setup Structure MONITORING
Absorption: Inactive (CMF -0.04)
Pullback / Drawdown: -58.4% from 52W High
Consolidation: Trending (ADX 20.8)
30D Insider Cluster Signal TRACKED
30D Insider Buyers: 0 insiders ($0)
30D Net Insider Flow: $-145,792

Quantitative Signal Breakdown

  • BULLISH: Price oversold vs 30-day range
  • BULLISH: Options cheap (IV 0th percentile)
  • BEARISH: Weak technical setup (36/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 72.7% below Wall St target ($10.00)
  • WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) 5.53
Wall Street Target $10.00 (+72.7%)
Revenue Growth (YoY) -52.4%
Earnings Growth (YoY) -93.8%
Profit Margin -40.2%
Valuation Discount vs History -21.6% cheaper
PE vs Historical 5.5 vs 11.5 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -21.6% (market-implied from PE analysis)
1-Year Target $5.21 (-10%)
2-Year Target $4.69 (-19%)
3-Year Target $4.22 (-27%)
3-Yr Target (if PE normalizes) (PE: 6→12) $8.77 (+52%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 19.9, Growth: 261.3%) $70.14 (+1111%)
Base: (SPY PE: 5.5, Growth: 261.3%) $19.54 (+238%)
Bear: (PE: 4.7, Growth: 261.3%) $16.61 (+187%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.5 to 11.5
Stabilization Target: $12.03 (+107.8%)
PE Expansion Potential: +107.8%
Share EBS Analysis

Share this live EBS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (EBS)

Bearish 2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 14, 2026
Daily AI digest
AI Retail Discussion Summary: A bullish StockTwits user with 243 followers expresses belief in the undervaluation of $SIGA and expects potential news or acquisition by $EBS, while expressing bearishness towards $ENPH and $SMCI.
Key Retail Themes: $SIGA undervaluation and potential acquisition by $EBS Bearish outlook on $ENPH and $SMCI
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 16, 2026 1:53 AM ET
Data refreshes hourly during market hours. Next update: 2:53 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for EBS.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NBIX
Neurocrine Biosciences I…
STRONG BUY
28 analysts
$208 30 SELL
ALKS
Alkermes Plc
STRONG BUY
20 analysts
$58 39 SELL
TEVA
Teva Pharma Industries L…
STRONG BUY
15 analysts
$49 47 HOLD
AMLX
Amylyx Pharmaceuticals I…
STRONG BUY
12 analysts
$43 55 HOLD
AQST
Aquestive Therapeutics I…
STRONG BUY
9 analysts
$9 59 HOLD

Advanced EBS Option Strategies

Professional options setups generated by AI based on today's EBS price and gamma walls.

Iron Condor Bull Call Bear Put Collar
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals